The Outcomes of Adenovirus Infection in Kidney Transplant Recipients
Transplant Infectious Disease · 2025
DOI: 10.1111/tid.14409 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Hay Me Me und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Mayo Clinic, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Graft Rejection, Adenoviridae Infections, Adenovirus Infections, Human. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Background
Adenovirus (ADV) infection can lead to significant morbidity and mortality in immunocompromised patients, particularly in those with hematopoietic stem cells or solid organ transplants. The incidence of ADV infection in kidney transplant (KT) is not well‐defined as ADV is often asymptomatic and not routinely checked.
Methods
This retrospective case‐series study included KT and simultaneous pancreas‐KT (SPKT) recipients from January 1, 2008, to January 31, 2024, across three Mayo Clinic sites (Arizona, Florida, and Minnesota) with symptomatic adenovirus polymerase chain reaction cases. The primary outcomes were allograft function at various intervals post‐ADV infection, allograft, and patient survival.
Results
We report one of the largest multi‐site case series regarding outcomes of ADV in KT with 17 patients. The median time to ADV infection was 30 weeks (5–74). Five patients (29%) developed disseminated infection. Nine patients (53%) of the entire cohort experienced graft loss within a median of 35 (4–168) weeks, with four (44%) of graft loss attributed to ADV. Nine patients (53%) developed rejections post‐ADV infection with a median of 4 (2–8) weeks after resolution. One patient died from acute hypoxic respiratory failure from ADV infection.
Conclusion
ADV should be considered in KT/SPKT patients with renal dysfunction, hematuria, and with or without fever. Despite the low mortality rate, there is a significant risk of graft loss and rejection after ADV infection. It is crucial to screen for ADV and develop intervention strategies for treatment. Further multicenter studies are needed to better define, stage, and manage ADV infection. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Mayo Clinic, Phoenix, Arizona, USA.
- Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
- Transplant Department, Mayo Clinic, Jacksonville, Florida, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Infectious Diseases, Mayo Clinic, Phoenix, Arizona, USA.
ORCID-Profile: Hay Me Me, Sumi Nair, Carrie A Schinstock, Tambi Jarmi, Nan Zhang, Pooja Budhiraja, Lavanya Kodali, Holenarasipur R Vikram, Girish Mour
Zitieren
APA
Me, H. M., Nair, S., Schinstock, C. A., Jarmi, T., Zhang, N., Budhiraja, P., Kodali, L., Vikram, H. R., & Mour, G. (2025). The Outcomes of Adenovirus Infection in Kidney Transplant Recipients. Transplant Infectious Disease. https://doi.org/10.1111/tid.14409
Vancouver
Me HM, Nair S, Schinstock CA, Jarmi T, Zhang N, Budhiraja P, et al. The Outcomes of Adenovirus Infection in Kidney Transplant Recipients. Transplant Infectious Disease. 2025. doi:10.1111/tid.14409
BibTeX
@article{Me2025,
author = {Me, Hay Me and Nair, Sumi and Schinstock, Carrie A and Jarmi, Tambi and Zhang, Nan and Budhiraja, Pooja and Kodali, Lavanya and Vikram, Holenarasipur R and Mour, Girish},
title = {The Outcomes of Adenovirus Infection in Kidney Transplant Recipients},
journal = {Transplant Infectious Disease},
year = {2025},
doi = {10.1111/tid.14409}
}
EUVIMED